Medical marijuana research comes in all shapes and sizes. Some
companies are diving into the use of Cannabis to help cure fatal
illnesses, while others are taking the plant and transforming it into
mainstream solutions for common everyday problems.
One company
that is trying to revolutionize the industry is AXIM Biotechnologies
with their new creation called CanChew Plus, which is believed to treat
stomach cramps, bloating and diarrhea associated with IBS.
What is IBS?
Irritable
Bowel Syndrome, aka IBS, is a common gut disorder. It’s quite a common
disorder that causing discomfort in the bowel. The symptoms can be quite
variable and include tummy pain, bloating and sometimes bouts of
diarrhea and/or constipation.
As of now, up to 20% of American
adults suffer from IBS at some point in their lives. While the exact
reasons as to why it occurs are still unknown, the American College of
Gastroenterology, clearly defined IBS by what it is not:
- It is not an anatomical or a structural problem.
- It is not an identifiable physical or chemical disorder.
- It is not a cancer and will not cause cancer.
- It will not cause other gastrointestinal diseases.
Cannabis Gum
According
to Renger Witkamp, a nutrition and pharmacology professor at Wageningen
University; “People often experience sudden flare-ups, and for many, it
has an adverse impact on their quality of life. CBD has shown to have
promising effects, but there has been a clear need for practical and
effective formulations.”
Cannabidiol (CBD)
comes in many forms, including oils and pills, but Witkamp believes
that gum will deliver a sustained release dosage of CBD in a highly
bioavailable form.
Axim also makes CanChew, a controlled-release
CBD chewing gum, and a combination CBD/THC gum called MedChew Rx, which
is currently undergoing clinical trials for the treatment of multiple
sclerosis-related pain and spasticity.
While standard CanChew gum
is already available in all 50 US states, Axim says that due to current
federal laws only contains hemp-based CBD.
According to Axim CEO
Anastassov, if the IBS trial is successful they will be ready to proceed
immediately with further trials on their pharmaceutical grade CanChew
Rx products to treat inflammatory bowel disease (IBD), ulcerative
colitis, and Crohn’s disease.
0 comments:
Post a Comment